All In Biotech

NDA 213876 · Eton

Alkindi Sprinkle

Hydrocortisone · Oral · Corticosteroid

Orphan

Last checked: Nov 19, 2026Latest source record: Jun 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Sep 29, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

753

149 Phase 3, 82 recruiting

FAERS reports

68,505

56,550 serious, 10,069 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 21, 2026.

ALKINDI SPRINKLE is indicated as replacement therapy in pediatric patients with adrenocortical insufficiency. ALKINDI SPRINKLE is a corticosteroid indicated as replacement therapy in pediatric patients with adrenocortical insufficiency. (1)

Mechanism: Hydrocortisone is a glucocorticoid. Glucocorticoids, adrenocortical steroids, cause varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli..

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • ALKINDI SPRINKLE · HYDROCORTISONE 2MG · GRANULE, ORAL · Prescription
  • ALKINDI SPRINKLE · HYDROCORTISONE 0.5MG · GRANULE, ORAL · Prescription
  • ALKINDI SPRINKLE · HYDROCORTISONE 5MG · GRANULE, ORAL · Prescription
  • ALKINDI SPRINKLE · HYDROCORTISONE 1MG · GRANULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydrocortisone" as an intervention, any sponsor and status, largest first.

All 753 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use9,694
  • drug ineffective7,644
  • fatigue6,094
  • condition aggravated5,566
  • nausea5,130
  • rash5,027
  • diarrhoea4,568
  • headache4,528
  • pain4,512
  • dyspnoea4,403
  • arthralgia4,390
  • pyrexia4,064

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004437
2005555
2006511
2007547
2008613
2009735
2010847
20111,083
20121,768
20131,542
20141,779
20152,440
20162,886
20173,318
20184,828
20194,318
20205,260
20215,540
20226,220
20236,179
20246,464
20256,284
20264,347

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,629 on PubMed

Sponsor: Eton

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.